BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 27075916)

  • 1. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
    Kim YA; Lee HJ; Heo SH; Park HS; Park SY; Bang W; Song IH; Park IA; Gong G
    Breast Cancer Res Treat; 2016 Apr; 156(3):597-606. PubMed ID: 27075916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.
    Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A
    Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling.
    Park IA; Hwang SH; Song IH; Heo SH; Kim YA; Bang WS; Park HS; Lee M; Gong G; Lee HJ
    PLoS One; 2017; 12(8):e0182786. PubMed ID: 28817603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer.
    Lee HJ; Park IA; Song IH; Shin SJ; Kim JY; Yu JH; Gong G
    J Clin Pathol; 2016 May; 69(5):422-30. PubMed ID: 26475777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
    Matsumoto H; Thike AA; Li H; Yeong J; Koo SL; Dent RA; Tan PH; Iqbal J
    Breast Cancer Res Treat; 2016 Apr; 156(2):237-47. PubMed ID: 26960711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
    Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
    Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
    Wang K; Shen T; Siegal GP; Wei S
    Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
    Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
    Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes.
    Kim JY; Heo SH; Choi SK; Song IH; Park IA; Kim YA; Park HS; Park SY; Bang WS; Gong G; Lee HJ
    Virchows Arch; 2017 Apr; 470(4):381-389. PubMed ID: 28185053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
    Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
    Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.
    Althobiti M; Aleskandarany MA; Joseph C; Toss M; Mongan N; Diez-Rodriguez M; Nolan CC; Ashankyty I; Ellis IO; Green AR; Rakha EA
    Histopathology; 2018 Dec; 73(6):887-896. PubMed ID: 29947077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
    Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
    Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling.
    Lee HJ; Song IH; Park IA; Heo SH; Kim YA; Ahn JH; Gong G
    Oncotarget; 2016 May; 7(21):30119-32. PubMed ID: 27121061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
    Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M
    Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating lymphocytes and CD8
    Vihervuori H; Autere TA; Repo H; Kurki S; Kallio L; Lintunen MM; Talvinen K; Kronqvist P
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3105-3114. PubMed ID: 31562550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.
    Lee HJ; Kim JY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
    Am J Clin Pathol; 2015 Aug; 144(2):278-88. PubMed ID: 26185313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.